International Journal of Neuroscience · 2020 · 13 citations · 16 references
MedicineImmunologyPediatricsClinical ImmunologyImmunopathologyPediatric ImmunologyAutoimmune DiseasesMyasthenia GravisPediatric Clinical ImmunologyComparative Disease SeverityDisease Severity EstimationDisease Severity IndexHospital Stay DurationJuvenile Myasthenia GravisLogistic RegressionNeutrophil-to-lymphocyte Ratio
Objectives This study aimed to investigate the influence of neutrophil-to-lymphocyte ratio (NLR) on the severity and short-time curative effect of myasthenia gravis (MG) in children.Methods Data of 132 MG children were retrospectively analyzed, and data of 140 healthy controls (HC group) in the same period were collected. The data of both groups were compared and analyzed.Results NLR of MG group was significantly higher than that of HC group (Z = 2.644, p = 0.008). According to NLR level, patients were divided into 3 groups: N1 (NLR < 1.03), N2 (NLR 1.03-2.17), and N3 (NLR > 2.17). Significant differences in white blood cell counts, course of disease, uric acid, albumin and the time of hospital stay among the 3 groups were observed (p < 0.05, 0.01). The results of logistic regression revealed that NLR (adjusted OR = 3.874, 95% CI 1.359-11.045, p = 0.011) was the risk factor of MG, and it was risk factor of higher QMG during admission (adjusted OR = 2.989, 95% CI 1.247-7.160, p = 0.014) as well. Using the NLR level for the MG diagnostic test, the area under the receiver operating characteristic (ROC) curve was 0.765 [95%CI (0.710-0.820), p = 0.000], with a cut-off value of 1.39, sensitivity of 0.833, and specificity of 0.479. Cox regression analysis suggested that NLR (N1: Wald = 9.262, p = 0.010, N2: HR = 12.267, 95%CI 2.432-61.863, p = 0.000, and N3: HR = 8.142, 95%CI 1.209-77.754, p = 0.032) was associated with poor efficacy at discharge. Elevated NLR was considered as an independent risk factor of poor outcomes during discharge.Conclusion NLR could reflect disease severity and short time curative effect in children with MG to some extent. It may also be a potential marker in indicating diagnosis and severity of MG in children.
16
Myasthenia gravis: recommendations for clinical research standards
Alfred Jaretzki, Richard J. Barohn, Raina M. Ernstoff et al. · The Annals of Thoracic Surgery · 2000 · 642 citations · Full text
Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis
Revital Aricha, Keren Mizrachi, Sara Fuchs et al. · Journal of Autoimmunity · 2010 · 105 citations · Full text
Serum cytokine and chemokine profiles in patients with myasthenia gravis
Akiyuki Uzawa, Naoki Kawaguchi, Keiichi Himuro et al. · Clinical & Experimental Immunology · 2014 · 79 citations · Full text
Medicine, Immunology, Pathobiology +12
Changes in inflammatory cytokine networks in myasthenia gravis
Akiyuki Uzawa, Tetsuya Kanai, Naoki Kawaguchi et al. · Scientific Reports · 2016 · 62 citations · Full text
Medicine, Immunology, Pathology +16